Finding new treatments for Alzheimer's disease by targeting tau proteins
Preclinical discovery of novel farnesyltransferase inhibitors for the treatment of Alzheimer's disease and related tauopathies
This study is exploring new medications for Alzheimer's disease that aim to lower harmful tau proteins in the brain, and it's showing promise in mice, which could lead to better treatments for people with the condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sanford Burnham Prebys Medical Discovery Institute NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10989929 on NIH RePORTER |
What this research studies
This research focuses on developing new drugs to treat Alzheimer's disease by targeting tau proteins, which are known to contribute to the disease's progression. The approach involves inhibiting a specific protein called farnesyltransferase, which is believed to help reduce the accumulation of harmful tau in the brain. By using a mouse model, researchers have shown that this method can decrease tau levels and improve behavior, suggesting potential benefits for human patients. The goal is to create effective treatments that can slow down or halt the progression of Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related tauopathies, particularly those in the early to moderate stages of the condition.
Not a fit: Patients with advanced Alzheimer's disease or those with other forms of dementia unrelated to tau pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly slow the progression of Alzheimer's disease and improve the quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting tau proteins for Alzheimer's treatment, but this specific approach using farnesyltransferase inhibitors is relatively novel.
Where this research is happening
La Jolla, United States
- Sanford Burnham Prebys Medical Discovery Institute — La Jolla, United States (Active)
Researchers
- Principal investigator: Olson, Steven H — Sanford Burnham Prebys Medical Discovery Institute
- Study coordinator: Olson, Steven H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.